Geron Corporation (NASDAQ:GERN) Q4 2022 Earnings Call Transcript
Geron Corporation reported positive Phase 3 results for imetelstat in lower-risk MDS, planning NDA submission by mid-2023 and MAA by end of 2023. Anticipated U.S. and EU launches in 2024. Strong financial position with $445M cash, supporting operations through Q3 2025. Focused on commercial readiness and expanding imetelstat's applications in hematologic malignancies.
Reference News
Geron Corporation (NASDAQ:GERN) Q4 2022 Earnings Call Transcript
Geron Corporation reported positive Phase 3 results for imetelstat in lower-risk MDS, planning NDA submission by mid-2023 and MAA by end of 2023. Anticipated U.S. and EU launches in 2024. Strong financial position with $445M cash, supporting operations through Q3 2025. Focused on commercial readiness and expanding imetelstat's applications in hematologic malignancies.